Episode 60 – Devyn Smith – CEO Arbor Biotechnologies

Welcome back to another episoe of The Bio Hub, we were delighted to be joined by Dr. Devyn Smith, a widely respected executive and thought leader in the field of cell and gene therapy, with a career that spans both global pharmaceutical giants and pioneering biotech startups.Devyn is currently the Chief Executive Officer of Arbor Biotechnologies, a company at the forefront of next-generation gene editing, co-founded by CRISPR pioneer Feng Zhang. Arbor is developing a proprietary platform of CRISPR-based editors and therapeutic programs aimed at tackling serious genetic diseases, with a focus on in vivo delivery and precision editing.Before joining Arbor, Devyn served as Chief Operating Officer at Sigilon Therapeutics, where he helped guide the company through its IPO and led its strategic and operational functions, including clinical, manufacturing, and regulatory efforts. Prior to that, he held multiple senior roles at Pfizer, including Head of Strategy for the Rare Disease Research Unit and Chief of Staff to the President of Worldwide R&D.Beyond the executive suite, Devyn serves as a board member Alliance for Regenerative Medicine (ARM), where he played a key role in advocating for science-forward policy, expanding regulatory frameworks for advanced therapies, and pushing for sustained federal funding in biomedical research. He remains an active voice in the industry on issues ranging from AAV development and IND readiness to market access and public trust in gene-editing technologies.Devyn holds a Ph.D. in Genetics and Molecular Biology from the University of North Carolina and began his career in research before transitioning into strategy, development, and executive leadership.